JNJ

192.13

-0.88%↓

ABT

127.78

-1.34%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

JNJ

192.13

-0.88%↓

ABT

127.78

-1.34%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

JNJ

192.13

-0.88%↓

ABT

127.78

-1.34%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

JNJ

192.13

-0.88%↓

ABT

127.78

-1.34%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

JNJ

192.13

-0.88%↓

ABT

127.78

-1.34%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

Search

Catalyst Pharmaceuticals Inc

Cerrado

SectorSalud

21.34 1.96

Resumen

Variación precio

24h

Actual

Mínimo

20.94

Máximo

21.48

Métricas clave

By Trading Economics

Ingresos

-4.6M

52M

Ventas

5.1M

147M

P/B

Media del Sector

12.733

37.461

Margen de beneficio

35.553

Empleados

181

EBITDA

5.9M

79M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+57.07% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-79M

2.6B

Apertura anterior

19.38

Cierre anterior

21.34

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

153 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

Catalyst Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

21 oct 2025, 23:55 UTC

Acciones populares

Stocks to Watch: DraftKings, Texas Instruments, Intuitive Surgical, Pegasystems

21 oct 2025, 23:49 UTC

Ganancias

Texas Instruments Warns of Slower Semiconductor Industry Recovery -- Update

21 oct 2025, 21:40 UTC

Ganancias

Waste Connections 3Q Revenue Rises

21 oct 2025, 21:14 UTC

Ganancias
Principales Movimientos del Mercado

Intuitive Surgical 3Q Profit, Sales Jump, Sees Higher da Vinci Procedure Growth -- Update

21 oct 2025, 21:05 UTC

Adquisiciones, fusiones, absorciones

GE Vernova to Acquire Full Stake in Prolec GE Joint Venture

21 oct 2025, 20:57 UTC

Adquisiciones, fusiones, absorciones

DraftKings to Launch Prediction Markets Platform

21 oct 2025, 20:38 UTC

Ganancias

Intuitive Surgical 3Q Profit, Sales Jump, Sees Higher da Vinci Procedure Growth

21 oct 2025, 20:35 UTC

Ganancias

Capital One 3Q Sales, Profit Jump

21 oct 2025, 20:32 UTC

Ganancias

Texas Instruments 3Q Revenue Up on Growth Across End Markets

21 oct 2025, 23:44 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

21 oct 2025, 23:44 UTC

Charlas de Mercado

Nikkei May Rise on Weaker Yen, Hopes for Takaichi's Econ Steps -- Market Talk

21 oct 2025, 23:39 UTC

Charlas de Mercado

Gold Consolidates; May Undergo Further Technical Correction -- Market Talk

21 oct 2025, 23:36 UTC

Charlas de Mercado

BHP Has Hidden Leverage to Gold's Rush -- Market Talk

21 oct 2025, 22:55 UTC

Adquisiciones, fusiones, absorciones

Scentre Says This Forms Part of Capital Management Strategy

21 oct 2025, 22:55 UTC

Adquisiciones, fusiones, absorciones

Scentre: Continues to Evaluate Strategic Opportunities Including New JV Partners

21 oct 2025, 22:54 UTC

Adquisiciones, fusiones, absorciones

Scentre Notes Media Report on Possible Sale of Stake in Westfield Chermside to Dexus Fund

21 oct 2025, 21:09 UTC

Charlas de Mercado
Ganancias

Netflix Creators Have Started Using AI in Production -- Market Talk

21 oct 2025, 20:58 UTC

Charlas de Mercado
Ganancias

Netflix Aims to Build on 'KPop Demon Hunters' Mania -- Market Talk

21 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

21 oct 2025, 20:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Financial Services Roundup: Market Talk

21 oct 2025, 20:43 UTC

Ganancias

Netflix Stock Drops After Earnings Miss Estimates -- Barrons.com

21 oct 2025, 20:41 UTC

Ganancias

Dow Industrials Hit Record, Boosted by Strong Earnings -- WSJ

21 oct 2025, 20:33 UTC

Adquisiciones, fusiones, absorciones

GE Vernova: Deal Accelerates Growth for Electrification Segment >GEV

21 oct 2025, 20:33 UTC

Adquisiciones, fusiones, absorciones

GE Vernova Acquiring Remaining 50% Stake of JV From Xignux >GEV

21 oct 2025, 20:32 UTC

Adquisiciones, fusiones, absorciones

GE Vernova: Prolec GE Expects Low Double-Digit Rev Growth in Coming Years >GEV

21 oct 2025, 20:32 UTC

Adquisiciones, fusiones, absorciones

GE Vernova: Prolec GE Expects $3B in Rev at 25% Adj EBITDA Margin in 2025 >GEV

21 oct 2025, 20:32 UTC

Adquisiciones, fusiones, absorciones

GE Vernova: $5.275B Purchase Price at Closing, Expected to Be Funded Equally With Cash & Debt >GEV

21 oct 2025, 20:32 UTC

Adquisiciones, fusiones, absorciones

GE Vernova Will Acquire Remaining 50% Stake of Prolec GE >GEV

21 oct 2025, 20:31 UTC

Adquisiciones, fusiones, absorciones

GE Vernova To Fully Acquire Prolec GE Joint Venture >GEV

21 oct 2025, 20:29 UTC

Ganancias

Northrop Stock Tumbles on Sales Disappointment. When Good Isn't Good Enough. -- Barrons.com

Comparación entre iguales

Cambio de precio

Catalyst Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

57.07% repunte

Estimación a 12 meses

Media 33 USD  57.07%

Máximo 35 USD

Mínimo 31 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

5

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

N/A / 24.28Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

153 / 371 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.
help-icon Live chat